Andjelka Stones/Pinterest
Jun 5, 2026, 15:53
Andjelka Stones: Key Findings on Hemophilia A Gene Therapy
Andjelka Stones, Former Distinguished Adjunct Professor at NorthCentral University, shared a post on LinkedIn:
“Hemophilia A Gene Therapy
Gene therapy for hemophilia A: 4‑year data from the Phase 3 GENEr8‑1 trial are out.
Key findings (n=134):
- Mean treated bleed rate 82.6% from baseline
- Factor VIII infusion rate 95.5%
- 73.6% of patients had zero treated bleeds in year 4
- Mean FVIII activity at year 4: 16.1 IU/dL
- Only 18% of patients resumed prophylaxis
No new safety signals were observed. Health‑related quality of life remained improved.
This is the longest and largest Phase 3 follow‑up of a gene therapy in hemophilia.
Durable benefit after a single infusion.
Full citation in my archive.”
Stay updated with Hemostasis Today.
-
Jul 26, 2026, 01:48Rob Maloney: Why Global Diagnosis is the Missing Piece in Bleeding Disorder Care
-
Jul 26, 2026, 01:35Moustafa Abdou: Ehlers-Danlos Syndrome – Why Collagen Matters for Hemostasis
-
Jul 26, 2026, 01:25Vrisha Shah: Exploring Transgenic Mouse Models for Pregnancy Outcomes at ISTH 2026
-
Jul 26, 2026, 01:06Christine Bork: Why Misinformation Around a Single Vitamin Postpartum is Putting Babies at Risk
-
Jul 26, 2026, 00:44A Significant Step Forward For People With Bleeding Disorders In The Dominican Republic – WFH
-
Jul 25, 2026, 18:00The Evolving Landscape of Factor Replacement Therapy – EAHAD
-
Jul 25, 2026, 17:43Heghine Khachatryan: Advancing Care for Women and Girls With Hemophilia
-
Jul 25, 2026, 17:00Revathy R Menon: A Memorable Milestone at the 39th ISBT Congress
-
Jul 25, 2026, 16:19Nicola Potere: From Scientific Exchange to Global Collaboration at ISTH 2026